Article information
Abstract
In the present study we used two groups of Candida dubliniensis strains: one containing fluconazole-susceptible clinical isolates and another containing fluconazole-resistant laboratory derivative from the former to examine the changes on susceptibility accompanying the development of resistance to fluconazole. Our findings confirmed the ability of C. dubliniensis isolates to become resistant to fluconazole and indicated that this resistance was crossed with ketoconazole, itraconazole, ravuconazole and terbinafine. We also tested combinations of terbinafine, amphotericin B, itraconazole and voriconazole against both groups of isolates in a checkerboard assay. Surprisingly, most combinations evidenced indifferent interactions, and the best synergism appeared when terbinafine and itraconazole were combined against the fluconazole-resistant group.
Keywords:
Candida
Antifungal agents
Fluconazole
Drug resistance, fungal
Full text is only aviable in PDF
References
[1.]
M.D. Johnson, C. MacDougall, L. Ostrosky-Zeichner, et al.
Combination antifungal therapy.
Antimicrob Agents Chemother, 48 (2004), pp. 693-715
[2.]
J.A. Vazquez.
Combination antifungal therapy against Candida species: the new frontier – are we there yet?.
Med Mycol, 41 (2003), pp. 355-368
[3.]
V.N. Tariq, E.M. Scott, N.E. McCain.
Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro.
Antimicrob Agents Chemother, 39 (1995), pp. 2615-2619
[4.]
F. Barchiesi, L.F. Di Francesco, P. Compagnucci, et al.
In vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans.
J Antimicrob Chemother, 41 (1998), pp. 59-65
[5.]
E. Cantón, J. Pemán, M. Gobernado, et al.
Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.
Antimicrob Agents Chemother, 49 (2005), pp. 1593-1596
[6.]
M. Weig, F.C. Müller.
Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Antimicrob Agents Chemother, 45 (2001), pp. 966-968
[7.]
D.J. Sullivan, T.J. Westerneng, K.A. Haynes, et al.
Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals.
Microbiology, 141 (1995), pp. 1507-1521
[8.]
G.P. Moran, D.J. Sullivan, M.C. Henman, et al.
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
Antimicrob Agents Chemother, 41 (1997), pp. 617-623
[9.]
K. Fekete-Forgács, L. Gyürc, B. Lcnkcy.
Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans.
Mycoses, 43 (1999), pp. 273-279
[10.]
Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing yeasts 3rd ed. Approved standard M27-A3. Clinical Laboratory and Standards Institute 2008. Wayne, PA.
[11.]
M. Martinez, J.L. Lopez-Ribot, W.R. Kirkpatrick, et al.
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
J Clin Microbiol, 40 (2002), pp. 3135-3139
[12.]
W.R.S. Kirkpatrick, S.G. Revankar, R.K. McAtee, et al.
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates.
J Clin Microbiol, 36 (1998), pp. 3007-3012
[13.]
M.A. Ghannoum, B. Elewski.
Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine.
Clin Diagn Lab Immunol, 6 (1999), pp. 921-923
[14.]
C. Gil-Lamaignere, F.M.C. Müller.
Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr.
Int J Antimicrob Agents, 23 (2004), pp. 520-523
[15.]
S. Perea, G. Gonzalez, A.W. Fothergill, et al.
In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.
J Clin Microbiol, 40 (2002), pp. 1831-1833
Copyright © 2012. Elsevier Editora Ltda.. All rights reserved
